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Directed modulation of the colonic bacteria to metabolize lactose
effectively is a potentially useful approach to improve lactose di-
gestion and tolerance. A randomized, double-blind, multisite pla-
cebo-controlled trial conducted in human subjects demonstrated
that administration of a highly purified (>95%) short-chain galac-
tooligosaccharide (GOS), designated “RP-G28,” significantly im-
proved clinical outcomes for lactose digestion and tolerance. In
these individuals, stool samples were collected pretreatment (day
0), after GOS treatment (day 36), and 30 d after GOS feeding stop-
ped and consumption of dairy products was encouraged (day 66). In
this study, changes in the fecal microbiome were investigated using
16S rRNA amplicon pyrosequencing and high-throughput quantita-
tive PCR. At day 36, bifidobacterial populations were increased in 27
of 30 of GOS subjects (90%), demonstrating a bifidogenic response
in vivo. Relative abundance of lactose-fermenting Bifidobacterium,
Faecalibacterium, and Lactobacillus were significantly increased in
response to GOS. When dairy was introduced into the diet, lactose-
fermenting Roseburia species increased from day 36 to day 66. The
results indicated a definitive change in the fecal microbiome of lac-
tose-intolerant individuals, increasing the abundance of lactose-
metabolizing bacteria that were responsive to dietary adaptation
to GOS. This change correlated with clinical outcomes of improved
lactose tolerance.
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Alimited ability to digest lactose occurs when the intestinallactase enzyme is reduced in the brush border of the small
bowel mucosa. Consumption of dairy foods by lactose-intolerant
individuals may result in clinical symptoms including abdominal
pain, diarrhea, bloating, flatulence, and abdominal cramping. In
these cases, lactose travels through the gastrointestinal tract and
is fermented in the colon, producing acetate, carbon dioxide,
hydrogen gas, and methane by gas-producing microbes. Ap-
proximately 75% of the global human population are lactose
maladsorbers (1, 2). In the United States, it is estimated that up
to 80 million Americans are at risk for lactose intolerance.
Efforts to address lactose intolerance include avoidance of
dairy foods, reduction in the lactose content of milk through
treatment with microbial lactases, and the use of lactase enzymes
to process milk before dairy consumption (3). Savaiano et al.
conducted a randomized, double-blind, parallel-group, placebo-
controlled study at two sites in the United States (4). A high
purity (>95%) galactooligosaccharide (GOS/RP-G28) or a pla-
cebo (Sweetose; Tate & Lyle Ingredients) was administered in
increasing doses to 62 lactose-intolerant subjects for 36 d. Subjects
refrained from consuming lactose during the GOS treatment pe-
riod. After GOS treatment, subjects reintroduced dairy products
into their diets for an additional 30 d and then were challenged for
lactose digestion and were evaluated for symptoms improvement via
a Likert scale. Subjects consuming GOS trended toward improve-
ment in overall symptoms after 36 d of GOS feeding and for an
additional 30 d after GOS treatment that included a dairy diet.
Subjects on GOS were six times more likely than control subjects
to claim they were lactose tolerant after dairy foods had been
reintroduced into their diets posttreatment (P = 0.0389).
GOS are short-chain galactooligosaccharides comprising two
to five residues of galactose terminating with an N-terminal
glucose that form lactose as a terminal disaccharide within the
molecule. These oligosaccharides are not digestible by humans
but are readily fermented by some members of the commensal
microbiota capable of fermenting GOS and lactose, notably lac-
tobacilli and bifidobacteria, and also by other microbial members
of the intestinal community (5). The pathway for GOS utilization
was demonstrated for Lactobacillus acidophilus (6) and was shown
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to be driven by the LacS permease that transports both lactose and
GOS into the bacterium. GOS then is broken down intracellularly
by galactosidases, and eventually β-galactosidase hydrolyzes the
terminal lactose. GOS consumption has been reported to promote
the growth of bifidobacteria in the human gastrointestinal tract, a
bifidogenic response widely considered beneficial because intrinsic
Bifidobacterium populations were elevated (5).
The objective of this study was to investigate whether a shift
occurred in the fecal microbiome of lactose-intolerant human
subjects who were treated with GOS and a dairy diet and who
exhibited a clinical response toward lactose tolerance. Fecal
samples were taken at day 0, day 36, and day 66, and microbiome
changes were evaluated by 16S rRNA amplicon sequencing and
high-throughput quantitative PCR (qPCR) within each subject
over the three time points to determine if changes occurred in the
microbiome of lactose-intolerant individuals consuming GOS.
Results
Experimental Design and Chemical Composition of GOS/RP-G28.
Subjects with a self-reported history of lactose intolerance were
assessed via a hydrogen breath test (HBT) after a 25-g lactose
challenge. Individuals with a minimum symptom score and a
positive HBT were randomly assigned to either GOS- or placebo-
treatment groups (2:1). The placebo was corn syrup (Sweetose)
with a consistency and sweetness similar to GOS and was used at
the same dosing schedule and with the same packaging. GOS and
placebo were escalated in 5-d increments from 1.5 g to 15 g
consumed once a day. The subjects avoided dairy during the 35-d
treatment. After completion of the treatment period, subjects
were instructed to reintroduce dairy foods into their diets. Stool
samples from the treatment and placebo groups were collected at
days 0, 36, and 66 (4). The GOS preparation used throughout this
study and in the prior clinical study by Savaiano et al. (4), designated
“RP-G28” (Ritter Pharmaceuticals, Inc.), was >95%GOS (Table 1).
Characterization of the Gut Microbiome of Lactose-Intolerant Individuals.
Microbiome metrics of fecal samples from patients enrolled in a
randomized, double-blind, parallel-group, placebo-controlled study
conducted to test the effectiveness of RP-G28 in two sites in the
United States (4) by terminal restriction length polymorphism
analysis (T-RFLP) and 16S rRNA amplicon pyrosequencing.
T-RFLP analysis was conducted in all treatment and placebo
samples (n = 380). At the time of this analysis, T-RFLP was a
cost-effective method for analyzing the composition of the gut
microbiome in a large number of samples. Placebo samples
were analyzed only by T-RFLP and showed no changes in
microbiome composition over time (Fig. 1A); therefore we performed
16S rRNA gene sequencing only on GOS samples. In the GOS group,
the baseline samples (day 0) served as each individual’s own control.
T-RFLP analysis is based on PCR amplification and endonuclease
restriction-generated fragments which permit a qualitative assessment
of unique bacterial groups present, even rare ones, but do not provide
information about the relative abundance of any given bacterial spe-
cies. In this study, peak files for all samples were compressed in silico
to identify unique terminal restriction fragments (TRFs). A direct
comparison of unique TRFs represented in at least 3% (if TRFs were
binned, 2% if not) of the total samples from treatment and placebo
showed a significant change in the number of TRFs that were dif-
ferentially represented (over- or underrepresented) (79 unique
peaks) in day 36 samples from the treatment group compared with
the placebo group (Fig. 1A). Moreover, a dramatic change oc-
curred in the GOS treatment group at day 66, after the cessation
of GOS at day 36 and the addition of dairy to the diet. This
analysis represents only changes in number of unique TRFs
without discriminating between positive or negative changes.
We next performed 16S rRNA amplicon pyrosequencing only
on samples from the treatment group (n = 307). We included the
three fecal samples obtained from each subject at three time
points (a total of nine samples per individual). Amplicon se-
quencing yielded a total of 911,970 sequences (2,990 ± 1,677 reads
per sample) and an average of 2,990 ± 1,679 operational taxonomic
units (OTUs) per sample. Sequencing data assigned the ma-
jority of OTUs to the phyla Firmicutes (48.7 ± 27.1%), Bac-
teroidetes (43.9 ± 26%), and Proteobacteria (1.0 ± 1.6%);
Table 1. Chemical composition of the GOS preparation RP-G28
used in the present study
Component % of GOS/RP-G28
Glucose <0.1
Galactose <0.1
Lactose <3.2
GOS total 95–97
GOS-1 (Hexa) 11–16
GOS-2 (Penta)
GOS-3 (Tetra) 26–30
GOS-4 (Tri) 56–59
GOS-5 (di) <0.2
GOS-6 (mono) 0.5–2.2
Fig. 1. Overall microbiome analysis of individuals fed GOS/dairy. (A) Unique TRFs differentially represented in each time point compared with day 0 for
subjects fed GOS (light gray line) versus the placebo/control groups (black line). Peak files for all samples were compressed in silico to identify unique TRFs. The
analysis represents only changes in the number of unique TRFs without discriminating between positive or negative changes. (B) Unweighted UniFrac-based
PCoA of microbial communities from individuals at day 0 (pretreatment; red dots), day 36 (GOS consumption; yellow dots), and day 66 (GOS halted, dairy
consumption encouraged; blue dots). Fecal samples were obtained in triplicate from each subject at three time points (a total of nine samples per individual) were
included in this analysis. ANOSIM- and PERMANOVA-generated parameters are indicated in the plot. PC1 and PC2, principal components 1 and 2.
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Fusobacteria, Tenericutes, Elusimicrobia, Actinobacteria, Syn-
ergistetes, Cyanobacteria, and Lentisphaerae were detected at
levels <1%, in agreement with previous reports of the human gut
microbiome composition (7). In addition, 5.5 ± 4% of sequences
were not assigned to any bacterial phylum. It should be noted
that while our study was underway the sequencing primers
used for 16S rRNA amplicon sequencing were reported to
underrepresent the phylum Actinobacteria and specifically
Bifidobacterium species (8).
More in-depth analysis by unweighted Unifrac similarity ma-
trices and subsequent analysis of similarities (ANOSIM) and
permutational multivariate analysis of variance (PERMANOVA)
analyses revealed a significant correlation (ANOSIM R = 0.218,
P = 0.0001; PERMANOVA pseudo-F = 3.4318, P = 0.0001) be-
tween microbiome composition and the day when GOS-fed sub-
jects were sampled (day 0 or baseline, and day 36 and day 66 as
categories) (Fig. 1B). The variance percent explained in the
principal coordinate analysis (PCoA) suggested that the micro-
biome of fecal samples from individuals at day 36 was not dra-
matically impacted by GOS, but at day 66, when dairy had been
reincorporated in the diet, the microbiome shifted to specific
microbial clusters. Grouping of samples by individual patient was
also statistically significant (ANOSIM R = 0.7064, P = 0.0001;
PERMANOVA pseudo-F = 2.1239, P = 0.0001). Finally, a
small but statistically significant (ANOSIM R < 0.2; P < 0.05,
PERMANOVA pseudo-F >1, P = 0.0001) effect on variables
was observed for the following factors: sex, weight, bloating,
cramping, and abdominal pain, and for the combined strata of
bloating, cramping, and abdominal pain by day. No effect was
observed for the factors location, diarrhea, and flatulence
(ANOSIM < 0.2, P > 0.05) (Table S1).
We observed significant differences (ANOVA with Tukey
pairwise comparisons P < 0.05) in Shannon diversity (H) and
species richness (S) indexes between groups at different days
(Fig. 2). Specifically, all samples had significantly lower diversity
and lower richness at day 66 than at day 0. Additionally, we
observed lower microbial diversity and richness values at day
66 in individuals reporting cramping (H = 4.38 ± 1.11 and S =
116.38 ± 38.66) than in individuals not reporting this symptom
(H = 5.27 ± 0.96 and S = 155.56 ± 37.66). No significant as-
sociations were identified between diversity and richness indexes
and sex for other gastrointestinal (GI) symptoms (bloating, flat-
ulence, diarrhea, or abdominal pain).
Impact of GOS on the Composition and Function of the Gut Microbiome.
To identify specific taxa affected by GOS consumption followed
by a lactose/dairy diet, we conducted pairwise comparisons at the
phylum and genus levels between days 0, 36, and 66 for indi-
viduals in the treatment group. Significant differences [Wilcoxon
signed-rank test with false-discovery rate (FDR) correction P <
0.05] in the relative abundance of the phyla Fusobacteria and
Actinobacteria were identified. The abundance of Fusobacteria
decreased at days 36 and 66 (Fig. S1), whereas Actinobacteria
showed a significant increase in responders at day 36 (see Fig. 4)
and then a decrease at day 66 following cessation of GOS
feeding. Analysis conducted at the genus level showed clear
changes in microbiome profiles at days 36 and 66 compared with
the baseline (day 0) (Fig. 3A and Table S2), with genera signif-
icantly (Wilcoxon signed-rank test P < 0.05; with FDR correction
P < 0.05) or borderline significantly (Wilcoxon signed-rank test
P < 0.05; with FDR correction P > 0.05) differentially repre-
sented in response to the interventions. In this analysis we in-
cluded over- or underrepresented taxa that were of borderline
significance because the applied FDR correction tends to be
overly restrictive, and because lineages that, based on our ex-
perience, were relevant for this study fell into that category.
Moreover, the sequencing primers used in the present study have
been reported to underrepresent the phylum Actinobacteria and
specifically Bifidobacterium species (8).
Fig. 2. Comparisons of Shannon diversity (H; number of species and species evenness) (Left) and species richness (S; number of species) (Right) indexes at day
0, day 36, and day 66 in all individuals (A) and in individuals reporting cramping (B). ANOVA analysis and Tukey tests were performed to identify statistically
significant differences in relative abundance between time points (P < 0.05). Yes, subject reports cramping; No, subject reports no cramping. Boxes represent
25–75%, and whiskers represent the 1.5 interquartile range. Horizontal lines within boxes represent median values.
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The most impacted phylum was Firmicutes, with 25 genera
modified, followed by Proteobacteria (five genera), Actinobacteria
(four genera), Bacteroidetes (two genera), and Fusobacteria (one
genus, Fusobacterium). Cluster analysis of significantly differen-
tially represented genera identified four different clusters (Fig. 3B).
Cluster I included taxa that were underrepresented at days 36 and
66 (i.e., their relative abundance showed a linear decrease over
time), cluster II included taxa that were overrepresented at days 36
and 66 (i.e., their relative abundance showed a linear increase over
time), cluster III included taxa that were underrepresented at
day 36 but were overrepresented at 66 (compared with the
previous time point), and cluster IV included taxa that were
overrepresented at day 36 but were underrepresented at day 66.
Genera in cluster I, interpreted as taxa suppressed by GOS and
dairy, included genera in Enterobacteriaceae, Streptococcus, Clos-
tridium, Lachnospira, Anaerotruncus, Ruminococcus, and others.
Cluster II, interpreted as taxa enhanced in the long term by GOS,
included the health-promoting genera Lactobacillus and Faecali-
bacterium; the latter was found at lower population levels in indi-
viduals with inflammatory bowel diseases (9, 10). Also enhanced in
population were Christensenellaceae (Christensenellaceae_other),
a poorly defined family enriched in individuals with a low body mass
index (BMI). The cluster also included undefined Lachnospiraceae
(Lachnospiraceae_2), Bulleidia, and a poorly characterized
group of Tenericutes (RF39_other). Cluster III, interpreted
as taxa suppressed by the GOS but not by dairy (or perhaps
enhanced by dairy) comprised most of the Firmicutes, in-
cluding lactose-fermenting Roseburia and other potential bu-
tyrate producers. Also included in the suppressed cluster at
day 36 following GOS feeding was Fusobacterium, a genus that
has been widely associated with adenomas and colorectal can-
cer (11–13). Finally, cluster IV, interpreted as taxa increased
by GOS but decreased when GOS feeding was halted, in-
cluded three Actinobacteria lineages: Bifidobacterium, undefined
Coriobacteriaceae (Coriobacteriaceae_other2), and Collinsella;
two Bacteroidetes: Prevotella and Bacteroidales_other1; and
four Firmicutes: Granulicatella in the Lactobacillales order,
Oscillospira, and undefined Clostridiaceae (Clostridiaceae_
other 2) in the Clostridiales order, and Catenibacterium in the
Erysipelotrichales order. Cluster I also included two Proteo-
bacteria and Tenericutes genera.
Analysis of predicted β-galactosidases from our 16S amplicon
sequencing dataset using Phylogenetic Investigation of Com-
munities by Reconstruction of Unobserved States (PICRUSt)
(14) showed a significant (Kruskal–Wallis P < 0.01) incremental
change in the relative abundance of ebgA, an evolved β-galac-
tosidase subunit α (EC:3.2.1.23), and a borderline significant
increase (P = 0.07) of lacA, β-galactosidase (EC:3.2.1.23), over
time (Table S3). The abundance of lacG, a 6-phospho-β-galac-
tosidase (EC:3.2.1.85), showed lower values over time.
Impact of GOS on Bifidobacterium Species of the Human Gut Microbiome
of Lactose-Intolerant Individuals. Increased abundance of Bifido-
bacterium has been reported following prebiotic consumption
(15, 16). Therefore, Bifidobacterium species were quantified in
stool samples from lactose-intolerant individuals who were
clinically responsive to dietary intervention with GOS. Two hun-
dred thirty-eight samples (of a total of 366), corresponding to
30 subjects at three time points (days 0, 36, and 66), were analyzed
by high-throughput qPCR using specific 16S rRNA gene and
GroEL probes. Data showed a significant increase at day 36 (Fig.
4) in the relative abundance of the phylum Actinobacteria (in-
creased 25-fold on average in treatment samples), the family
Bifidobacteriaceae (increased 14-fold), and the genus Bifido-
bacterium (increased onefold on average) in stool samples from
individuals consuming GOS as compared with controls (the
levels in the same individuals at day 0). At day 66 the abun-
dance of these taxa returned to baseline (day 0) levels.
Quantification of Bifidobacterium bifidum, Bifidobacterium
longum, Bifidobacterium dentium, Bifidobacterium adolescentis,
Bifidobacterium angulatum, Bifidobacterium catenulatum, Bifido-
bacterium lactis, Bifidobacterium breve, and Bifidobacterium gallicum
Fig. 3. (A) Statistically significant changes to the microbiome profiles of subjects at day 36 when receiving GOS and at day 66 d after dairy consumption was
resumed. The y axis shows the relative abundance of taxa impacted by either or both treatments. (B) Cluster analysis of taxa impacted by treatments. Each
panel represents the identified trends in log2-transformed relative abundances of bacteria in response to GOS and dairy. Two-dimensional heat maps and
trend plots of clusters I, II, III, and IV at the genus level provide visual representations of the direction and intensity of the changes in relative abundances
caused by each treatment. *P < 0.05, uncorrected Wilcoxon signed-rank test; **P < 0.05, FDR-corrected Wilcoxon signed-rank test.
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was carried out using species-specific 16S and GroEL primers (Fig.
5). The species B. longum (increased between 42- and 108-fold,
according to data obtained with GroEL and 16S primers, re-
spectively), B. adolescentis (increased between 45- and 8,212-fold),
B. catenulatum (increased between 25 and 1,874-fold), and B. breve
(increased an average of 46-fold detected by the GroEL probe)
were significantly overrepresented at day 36 compared with day 0,
whereas the abundance of B. dentium was significantly higher at day
66. The abundance of B. lactis and B. gallicum also increased at day
36, but the changes did not reach statistical significance. A linear fit
analysis was performed to assess the correlation between the 16S
rRNA gene and GroEL primers for detection of the same Bifido-
bacterium species. The analysis indicated a good correlation
(Pearson’s r >0.70) for B. longum, B. adolescentis, B. bifidum,
B. angulatum, and B. gallicum (Fig. S2); lower correlation in-
dices (Pearson’s r <0.70) were observed for B. catenulatum,
B. lactis, B. dentium, and B. breve (Table S4).
Correlations Between Changes in the Gut Microbiome and Clinical
Findings. In this study, the longitudinal high-throughput qPCR
analysis of samples showed a bifidogenic response in 90% (27/
30) of treated individuals (Fig. S3 A–D), with only three obvious
nonresponders (Fig. S3E). Regarding a symptomatic response,
71% (25/35) of treated individuals reported alleviation of at least
one symptom (pain, bloating, diarrhea, cramping, or flatulence)
after GOS feeding at day 33, and 69% (24/35) reported symptom
alleviation at day 66 when dairy was reintroduced into the diet
(4). The three subjects who did not show a bifidogenic response
were symptomatic responders. All symptomatic nonresponders
demonstrated a bifidogenic response.
A repeated-measures logistic regression model was applied to
identify positive or negative correlations between specific bac-
teria and symptoms (Fig. 6). In this model the estimate values
indicate how much the response (log odds of reporting each
symptom) increases for a one-unit increase in the predictor
(bacteria). Our data showed negative estimate values (indicating
that an increase in the group was associated with a decreased
likelihood of the symptom) for Bifidobacterium in association
with pain and cramping outcomes, whereas positive estimates
values were observed for Coprobacillus and the family Rick-
enellaceae in association with the same symptoms. Fig. 6 shows
all positive and negative correlations between bacterial occur-
rences and reported symptoms.
Discussion
This study demonstrates modulation of the gut microbiome of
lactose-intolerant individuals by GOS. The high-purity (>95%)
prebiotic significantly modified the microbiome composition at
day 36 (based on T-RFLP analysis) and further manifested sig-
nificant alterations in diversity parameters (Shannon diversity
index and species richness) after dairy was reintroduced into the
diet of lactose-intolerant participants. The clinical trial included
subjects who consumed GOS but refrained from consuming dairy
for 36 d, then stopped GOS consumption and reintroduced dairy
into their diets for 30 additional days, until day 66. The changes
in microbiome composition reported here included increases in
lactose-fermenting Bifidobacterium, Lactobacillus, and Faecali-
bacterium, and those changes correlated with an improvement of
symptoms for lactose-intolerant subjects who were participating
in the study (4). In this aligned clinical study, 50% of the subjects
with abdominal pain at baseline reported no abdominal pain at
the end of treatment with GOS (at day 36), and at 30 d post-
treatment (at day 66) (P = 0.0190). Subjects fed GOS were
also six times more likely to claim lactose tolerance post-
treatment after dairy foods had been reintroduced into their
diets (P = 0.0389).
Our original hypothesis was that incremental GOS feeding
would adapt the microbiome to beneficial lactose-fermenting
bacteria that do not produce gas. Analysis of predicted β-galac-
tosidases showed incremental changes in the relative abundance
of ebgA, an evolved β-galactosidase subunit α (EC:3.2.1.23), and
lacA, β-galactosidase (EC:3.2.1.23), over time in response to
GOS and dairy feeding, suggesting that such microbiome adap-
tation occurred (Table S3). We also noted a decreased diversity
in the microbiome of subjects when dairy was reintroduced to
their diets (at day 66) after GOS-feeding was halted; this de-
creased diversity could be associated with the increased abun-
dance of Bifidobacterium and Lactobacillus species and a
concomitant increase in the intraluminal concentration of organic
acids, including acetate, butyrate, and lactate (17). Moreover, a
previous study showed that an animal-based diet (containing
cheese products) had a greater impact on the gut microbiota than a
plant-based diet consisting of grains, legumes, fruits, and vegetables
(18), although the study reported no changes in α-diversity. A
further decrease in microbiome diversity was noted in patients
reporting cramping at day 66 compared with individuals not
reporting that symptom at that time point. There are no reports in
the literature of changes in diversity in correlation with abdominal
cramping. No other symptom correlated with decreases in diversity.
In our study, at least 11 microbial genera were impacted
by GOS feeding, in contrast to a previous report (5) in which
GOS feeding was reported to enhance bifidobacteria selectively
without consistently increasing or decreasing other specific bac-
terial lineages. We observed an increased abundance of Bifido-
bacterium in response to GOS at day 36 that was confirmed
by high-throughput qPCR using bifidobacterial-specific primers.
B. longum, B. adolescentis, and B. catenulatum were increased in
response to GOS, as previously reported in vitro and in vivo (5).
In addition, the relative abundances of B. breve and B. dentium
were significantly higher at day 36 and 66, respectively. B. lon-
gum, B. adolescentis, B. catenulatum, and B. breve have been
reported to encode more than one type of β-galactosidase, a
Fig. 4. High-throughput qPCR determination of the relative abundance of Actinobacteria (Left), Bifidobacteriaceae (Center), and Bifidobacterium (Right) at
day 0 (pretreatment), day 36 (GOS consumption), and day 66 (GOS halted, dairy consumption encouraged). ANOVA analysis and Tukey tests were performed
to identify statistically significant differences in relative abundance between time points. *P < 0.05.
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glycolytic enzyme essential for GOS metabolism that typically is
genetically linked with a LacS permease responsible for trans-
port and internalization of GOS (6). B. dentium has been less
thoroughly characterized, is mostly associated with the oral
cavity, and recently was shown to be increased in the stools of
100- to 108-y-old centenarians living in Bama, Guangxi (China)
as compared with younger (80- to 99-y-old) elderly persons (19).
In our study, the longitudinal analysis of a cohort of GOS-
consuming individuals showed that 90% (27/30) had a bifido-
genic response at day 36 and that three were clear nonre-
sponders. These results significantly expand a previous report in
which the bifidogenic response to GOS occurred in 50% of
subjects fed a daily dose of 5 g/d (responders), whereas the other
subjects were consistent nonresponders (5). Our study used GOS
that was >95% pure for the oligosaccharide, with <5% con-
tamination by glucose, galactose, and lactose.
Faecalibacterium, Lactobacillus, and taxa of the family Chris-
tensenellaceae were among the taxa enhanced by GOS and a
subsequent dairy diet. Strains of the Lactobacillus genus are widely
acknowledged to be beneficial, and their properties have been
reviewed extensively (20). Given their widespread association with
a variety of different environments, including dairy, meat, vege-
table, and grain-fermented foods and as commensals in the gas-
trointestinal tract, this genus has been widely consumed and also
has been used in dietary supplements to promote general health
and well-being (21–23). Recent human microbiome studies have
identified Faecalibacterium prausnitzii as an organism with anti-
inflammatory properties and have reported it to be an indicator
microbial population that was lowered in subjects with Crohn’s
disease and ulcerative colitis (10, 24). In addition to GOS,
reported herein, Faecalibacterium also has been shown to be
stimulated by the fructooligosaccharide inulin, and specific strains
are reported to grow in host-derived substrates such as N-acetyl-
glucosamine (25). Finally, the Christensenellaceae family was
enhanced by GOS and dairy. This family has been reported to be
enriched in persons who have a low BMI. One culturable member
of this family, Christensenella minuta, was associated with reduced
weight gain and altered the microbiome in mice (26).
With the reintroduction of dairy to the diet, the relative
abundance of butyrate producers in the families Clostridiaceae
and Lachnospiraceae and the genus Roseburia increased. The
abundance of other Clostridia in the genera Clostridium, Lach-
nospira, Ruminococcus, Dialister, and Anaerotruncus actually
decreased at day 36 and day 66, highlighting the diversity of the
microbiome environment.
Fig. 5. Relative abundance of Bifidobacterium species at day 0 (pretreatment), day 36 (GOS consumption), and day 66 (GOS halted, dairy consumption
encouraged) using 16S rRNA-specific (Left) and groEL-specific (Right) primers. 16S rRNA-specific primers did not permit accurate quantification of B. breve at
days 0 and 36. ANOVA analysis and Tukey tests were performed to identify statistically significant differences in relative abundance between time points.
*P < 0.05.
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Regression analysis of data identified specific taxa positively or
negatively correlated with symptoms. Bifidobacterium showed a
negative correlation with cramping and pain. Interestingly, also
showing a negative correlation with those symptoms was the
family Victivallaceae, a taxon that contains one described spe-
cies, Victivallis vadensis, originally known as “strain CelloT” be-
cause it was isolated using cellobiose as a carbon source (27).
Bacterial strains capable of metabolizing cellobiose are also capa-
ble of metabolizing lactose. To our knowledge there are no reports
of direct correlations between occurrences of specific bacteria and
the likelihood of symptom outcome.
It is notable that many studies reported on GOS have used
impure material that often comprises only ∼50% GOS, with the
remainder being monosaccharides (glucose and galactose) and
lactose. In this study, highly purified GOS (>95% purity) was
found to alter the microbiome of lactose-intolerant subjects
significantly, and those changes correlated with positive symptom
responses for lactose tolerance (4). GOS plus subsequent dairy
consumption modulated a shift in the microbiome with increases
in the relative abundance of proven beneficial microbes (Lac-
tobacillus, Bifidobacterium, Faecalibacterium, and Roseburia) and
decreases in potentially detrimental taxa (Enterobacteriaceae) in
the individuals who responded.
Materials and Methods
Experimental Design. An overview of the original study design has been
reported previously (4). The study was a randomized, double-blind, parallel-
group, placebo-controlled study conducted at two sites in the United States.
The trial was approved by the Independent Investigational Review Board,
Inc., Plantation, FL, on February 15, 2011, and the research was carried out in
accordance with the clinical research practices defined in the Good Clinical
Practice Guidelines of the International Conference on Harmonization. After
informed consent was obtained, 395 eligible subjects underwent screening
assessments; of these, 85 were randomized (57 to RP-G28 and 28 placebo). In
the randomized population, 42% were male with a mean age of 41 y and
mean BMI of 27.1 (the ethnicity breakdown can be found in Table S5). There
were no obvious differences in the two treatment groups. Participants had a
self-reported history of dairy intolerance. Baseline lactose digestion was
measured by hydrogen production via the HBT, and lactose-intolerance
symptoms (abdominal pain, flatulence, cramping, bloating, and diarrhea)
were measured via a patient-reported symptom-assessment Likert scale after
a 25-g lactose challenge. Eligible subjects were required to demonstrate a
minimum symptom score and a positive HBT to be eligible for randomiza-
tion. Exclusion criteria included diabetes mellitus, GI motility disorders, irri-
table bowel syndrome, inflammatory bowel diseases, celiac disease, and
surgery that altered the normal function of the GI tract (4). During the
clinical trial, participants avoided lactose in their diets and received esca-
lating doses of high-purity (>95%) GOS or placebo (Sweetose) in 5-d incre-
ments according to a fixed schedule from 1.5 g/d to 15 g/d. At day 36,
treatment was stopped, and subjects were encouraged to consume lactose/
dairy until day 66. A total of 468 samples from 52 individuals (GOS and
placebo) were collected. Measurements were taken at the end of treatment
and 30-d posttreatment to evaluate changes in subjects’ lactose digestion
and symptoms from baseline.
DNA Isolation. Isolation of DNA and subsequent microbiome analyses were
done at the University of North Carolina Microbiome Core Facility. The
Microbiome Core is a University-approved recharge facility and Biosafety
Level 2 laboratory. Total DNA isolation was carried out using the DNeasy
Qiagen Blood and Tissue protocol (Qiagen). The Qiagen protocol was
modified to ensure optimal isolation of DNA from Gram-positive bacteria.
Briefly, 200 mg of sample were transferred to a microtube containing 0.2 g of
autoclaved glass beads (11 μm in diameter; Sigma) and 1.4 mL of ASL buffer
(Qiagen). Next, samples were homogenized in a TissueLyser II instrument for
2 min at 25 Hz. Two hundred microliters of a lysozyme solution (200 mg/mL)
were then added to the mix, which was incubated at 37 °C for 30 min fol-
lowing steps performed according to the manufacturer’s protocol.
Fig. 6. Volcano plots showing the −log10 (P value) (x axis) versus estimate values (y axis) of taxa significantly associated with specific symptoms. Estimate
values indicate how much the response (log odds of reporting each symptom) increases with a one-unit increase in the predictor (bacteria). A positive es-
timate value means an increase in the group was associated with an increased likelihood of outcome. A negative estimate value means an increase in the
group was associated with a decreased likelihood of outcome. Significant estimate values (FDR-adjusted P value <0.05) are represented in pink (negative) and
blue (positive).
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T-RFLP Analysis. From a total of 468 stool samples from 52 individuals (nine
samples per individual), 380 samples were successfully analyzed by T-RFLP as
previously described (28). The individuals 081 and 092 were unable to pro-
duce all nine samples, and samples were lacking from subjects 68, 73, 95,
102, 106, 115, and 118. Eighty samples failed despite several attempts. For
further details, see SI Materials and Methods.
16S rRNA Gene Amplicon Sequencing. Stool samples obtained in triplicate at
three time points (days 0, 33, and 66) from 36 lactose-intolerant individuals
consuming GOS were processed. In total, nine samples from each individual
were analyzed by 16S rRNA amplicon pyrosequencing. A total of 18 samples
did not yield enough reads and were discarded from subsequent analyses.
Individual fecal samples were compared for microbiome changes in that
subject from day 0 (prefeeding), at day 36 of GOS feeding, and at day 66, 33 d
after the cessation of GOS feeding and the reintroduction of dairy into the
diet. The study intentionally used each subject as his or her own control,
comparing the microbiome changes occurring within each specific individual
at each sampling time point.
Amplification and sequencing of the V1–V2 region of the bacterial 16S
rRNA gene was performed on total DNA from collected samples (n = 307) as
previously described (29, 30). Briefly, reaction master mixes contained the
Qiagen Hotstar HiFidelity Polymerase Kit (Qiagen) with a forward primer
composed of the Roche Titanium Fusion Primer A (5′-CCATCTCATCCCTGC-
GTGTCTCCGACTCAG-3′), a 10-bp Multiplex Identifier (MID) sequence
(Roche), and the universal bacterial primer 8F (5′-AGAGTTTGATCCTGGCT-
CAG-3′) (31). The reverse primer was composed of the Roche Titanium
Primer B (5′-CCTATCCCCTGTGTGCCTTGGCAGTCTCAG-3′), the identical 10-bp
MID sequence, and the reverse bacterial primer 338R (5′-GCTGCCTCC-
CGTAGGAGT-3′) (32). The 16S rRNA amplicons from the pooled sample were
sequenced on a 454 Genome Sequencer FLX Titanium instrument (Roche) in
the Microbiome Core Facility of the University of North Carolina at Chapel
Hill using GS FLX Titanium XLR70 sequencing reagents and the corre-
sponding protocols. Initial data analysis, base-pair calling, and trimming of
each sequence to yield high-quality reads were performed by Research
Computing at the University of North Carolina at Chapel Hill.
Sequencing Data Analysis. Bioinformatics analysis of 16S amplicon pyrose-
quencing data were conducted using the Quantitative Insights Into Microbial
Ecology (QIIME) v.1.8.0 software pipeline (33). The combined raw sequencing
data were demultiplexed and filtered; all reads with lengths less than 200 bp
and with a quality score below 25 were removed. After chimera (34) and
singleton removal, sequences were clustered into OTUs at 97% similarity
using UCLUST (35) and were aligned to build a phylogenetic tree (36). To
ensure an even sampling depth, a random selection of 652 sequences from
each sample was used for rarefaction analysis to measure alpha diversity
using observed species (S) and phylogenetic diversity metrics on rarefied
OTU tables. Eighteen samples had fewer than 652 reads per sample and
were excluded from subsequent statistical analysis of differences in diversity
and richness between groups. Beta diversity and PCoA also were calculated
within QIIME using weighted and unweighted Unifrac distances (37) be-
tween samples at a depth of 652 sequences per sample to evaluate dissim-
ilarities between the samples.
PICRUSt Analysis of 16S rRNA Amplicon-Sequencing Data. PICRUSt (14),
designed to deduce metagenomic information from 16S rRNA amplicon
sequencing data, was applied to sequencing data using the default settings
(version 0.9.1). The generated metagenomic tables then were entered
into the Human Microbiome Project unified metabolic analysis network
(HUMAnN) (38) pipeline (version 0.98) to sort individual genes into Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways representing varying
proportions of each imputed sample metagenome.
High-Throughput qPCR Detection of Bifidobacterium Species. We used the
Fluidigm BioMark HD 192.24 Integrated Fluidics Chip (Fluidigm Corporation)
for high-throughput qPCR experiments to detect specific Bifidobacterium
species genes, as previously described (39). (For further information, see SI
Materials and Methods.) Because of the depletion of DNA from a number of
samples, a total of 238 samples including 30 subjects at three time points
(days 0, 36, and 66) in triplicate were analyzed.
Statistical Analyses. We computed the distance matrix between OTUs using
ANOSIM and PERMANOVA tests within QIIME to evaluate similarities or
dissimilarities between groups. Paired t tests were used to identify significant
differences in phylogenetic diversity and species richness (S) between the
different time points, and the Wilcoxon signed-rank test was used to iden-
tify significant differences in bacterial taxa and metagenome pathways
between paired samples. All statistical analysis was performed in JMP
Genomics 10.0 (SAS). P values <0.05 were considered significant unless
otherwise stated.
For high-throughput qPCR data, the relative proportion of Bifidobacte-
rium species was computed based on the Livak method (40). Quantitation
cycle (Cq) values for each sample were normalized against the Cq value for
the universal primers. Fold differences in the different Bifidobacterium species
were calculated by the 2–ΔΔCt method. Paired t tests and ANOVA with
Tukey tests were conducted to assess statistically significant differences
between groups.
Finally, a repeated-measures logistic regression adjusted for sex with an
autocorrelation structure for the within-subject correlation matrix was per-
formed for each bacterial species and each condition (bloating, cramping,
diarrhea, flatulence, and pain) to identify positive and negative correlations
between specific bacteria and symptoms. “Day”was considered in the model
as a continuous variable. All the resulting P values then were adjusted for
multiple comparisons via the FDR method.
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